The DOI matches its Crossref record; 68 of the 68 references it cites were found in a registry or an index.
Systematic Review of Early Cardiometabolic Outcomes of the First Treated Episode of Psychosis
Abstract
CONTEXT: The increased mortality associated with schizophrenia is largely due to cardiovascular disease. Treatment with antipsychotics is associated with weight gain and changes in other cardiovascular risk factors. Early identification of modifiable cardiovascular risk factors is a clinical imperative but prospective longitudinal studies of the early cardiometabolic adverse effects of antipsychotic drug treatment other than weight gain have not been previously reviewed. OBJECTIVES: To assess the methods and reporting of cardiometabolic outcome studies of the first treated episode of psychosis, review key findings, and suggest directions for future research. DATA SOURCES: PsycINFO, MEDLINE, and Scopus from January 1990 to June 2010. STUDY SELECTION: Subjects were experiencing their first treated episode of psychosis. Subjects were antipsychotic naive or had been exposed to antipsychotics for a short known period at the beginning of the study. Cardiometabolic indices were assessed. Studies used a longitudinal design. DATA EXTRACTION: Sixty-four articles were identified describing 53 independent studies; 25 studies met inclusion criteria and were retained for detailed review. DATA SYNTHESIS: Consolidated Standards of Reporting Trials and Strengthening the Reporting of Observational Studies in Epidemiology checklists were used to assess the methods and reporting of studies. A qualitative review of findings was conducted. CONCLUSIONS: Two key hypotheses were identified based on this review: (1) in general, there is no difference in cardiovascular risk assessed by weight or metabolic indices between individuals with an untreated first episode of psychosis and healthy controls and (2) cardiovascular risk increases after first exposure to any antipsychotic drug. A rank order of drugs can be derived but there is no evidence of significant class differences. Recommended directions for future research include assessing the effect on cardiometabolic outcomes of medication adherence and dosage effects, determining the therapeutic window for antipsychotic use in adults and youth, and testing for moderation of outcomes by demographic factors, including sex and age, and clinical and genetic factors.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
von Elm, E., Altman, D. G., Egger, M., Pocock, S. J., Gøtzsche, P. C., Vandenbroucke, J. P., & Initiative, F. T. S. (2007) · PLoS Medicine · doi:10.1371/journal.pmed.0040296 · Cited by 23,020
Vandenbroucke, J. P., von Elm, E., Altman, D. G., Gøtzsche, P. C., Mulrow, C. D., Pocock, S. J., Poole, C., Schlesselman, J. J., Egger, M., & Initiative, F. T. S. (2007) · PLoS Medicine · doi:10.1371/journal.pmed.0040297 · Cited by 8,613
Moher, D., Schulz, K. F., & Altman, D. G. (2001) · The Lancet · doi:10.1016/s0140-6736(00)04337-3 · Cited by 5,373
The Revised CONSORT Statement for Reporting Randomized Trials: Explanation and Elaboration
Altman, D. G., Schulz, K. F., Moher, D., Egger, M., Davidoff, F., Elbourne, D., Gøtzsche, P. C., Lang, T., & for the CONSORT Group (2001) · Annals of Internal Medicine · doi:10.7326/0003-4819-134-8-200104170-00012 · Cited by 3,835
Vandenbroucke, J. P., Elm, E. V., Altman, D. G., Gøtzsche, P. C., Mulrow, C. D., Pocock, S. J., Poole, C., Schlesselman, J. J., Egger, M., & initiative, F. T. S. (2007) · Annals of Internal Medicine · doi:10.7326/0003-4819-147-8-200710160-00010-w1 · Cited by 3,543
Moher, D., Schulz, K. F., & Altman, D. G. (2001) · BMC Medical Research Methodology · doi:10.1186/1471-2288-1-2 · Cited by 2,755
Lichtenstein, P., Yip, B. H., Björk, C., Pawitan, Y., Cannon, T. D., Sullivan, P. F., & Hultman, C. M. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60072-6 · Cited by 2,125
Tiihonen, J., Lönnqvist, J., Wahlbeck, K., Klaukka, T., Niskanen, L., Tanskanen, A., & Haukka, J. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60742-x · Cited by 1,354
Kahn, R. S., Fleischhacker, W. W., Boter, H., Davidson, M., Vergouwe, Y., Keet, I. P., Gheorghe, M. D., Rybakowski, J. K., Galderisi, S., Libiger, J., et al. (2008) · The Lancet · doi:10.1016/s0140-6736(08)60486-9 · Cited by 1,088
Physical Health Monitoring of Patients With Schizophrenia
Marder, S. R., Essock, S. M., Miller, A. L., Buchanan, R. W., Casey, D. E., Davis, J. M., Kane, J. M., Lieberman, J. A., Schooler, N. R., Covell, N., et al. (2004) · American Journal of Psychiatry · doi:10.1176/appi.ajp.161.8.1334 · Cited by 812
Rummel-Kluge, C., Komossa, K., Schwarz, S., Hunger, H., Schmid, F., Lobos, C. A., Kissling, W., Davis, J. M., & Leucht, S. (2010) · Schizophrenia Research · doi:10.1016/j.schres.2010.07.012 · Cited by 675
Pratt, L. A., Ford, D. E., Crum, R. M., Armenian, H. K., Gallo, J. J., & Eaton, W. W. (1996) · Circulation · doi:10.1161/01.cir.94.12.3123 · Cited by 643
Twenty-five year mortality of a community cohort with schizophrenia
Brown, S., Kim, M., Mitchell, C., & Inskip, H. (2010) · British Journal of Psychiatry · doi:10.1192/bjp.bp.109.067512 · Cited by 601
Medication adherence of individuals with a first episode of psychosis
Coldham, E. L., Addington, J., & Addington, D. (2002) · Acta Psychiatrica Scandinavica · doi:10.1034/j.1600-0447.2002.02437.x · Cited by 413
Association of antipsychotic druginduced weight gain with a 5-HT2C receptor gene polymorphism
Reynolds, G. P., Zhang, Z.-J., & Zhang, X.-B. (2002) · The Lancet · doi:10.1016/s0140-6736(02)08913-4 · Cited by 412
Lieberman, J. A., Tollefson, G., Tohen, M., Green, A. I., Gur, R. E., Kahn, R., McEvoy, J., Perkins, D., Sharma, T., Zipursky, R., et al. (2003) · American Journal of Psychiatry · doi:10.1176/appi.ajp.160.8.1396 · Cited by 404
The Distribution of Body Mass Index Among Individuals With and Without Schizophrenia
Allison, D. B., Fontaine, K. R., Heo, M., Mentore, J. L., Cappelleri, J. C., Chandler, L. P., Weiden, P. J., & Cheskin, L. J. (1999) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v60n0402 · Cited by 390
McEvoy, J. P., Lieberman, J. A., Perkins, D. O., Hamer, R. M., Gu, H., Lazarus, A., Sweitzer, D., Olexy, C., Weiden, P., & Strakowski, S. D. (2007) · American Journal of Psychiatry · doi:10.1176/ajp.2007.164.7.1050 · Cited by 377
Risperidone and Haloperidol in First-Episode Psychosis: A Long-Term Randomized Trial
Schooler, N., Rabinowitz, J., Davidson, M., Emsley, R., Harvey, P. D., Kopala, L., McGorry, P. D., Van Hove, I., Eerdekens, M., Swyzen, W., et al. (2005) · American Journal of Psychiatry · doi:10.1176/appi.ajp.162.5.947 · Cited by 348
Lieberman, J. A., Phillips, M., Gu, H., Stroup, S., Zhang, P., Kong, L., Ji, Z., Koch, G., & Hamer, R. M. (2003) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300157 · Cited by 345
Rate of Cannabis Use Disorders in Clinical Samples of Patients With Schizophrenia: A Meta-analysis
Koskinen, J., Lohonen, J., Koponen, H., Isohanni, M., & Miettunen, J. (2010) · Schizophrenia Bulletin · doi:10.1093/schbul/sbp031 · Cited by 320
Metabolic syndrome and mental illness.
Newcomer, J. W. (2007) · PubMed · Cited by 285
Templeman, L. A., Reynolds, G. P., Arranz, B., & San, L. (2005) · Pharmacogenetics and Genomics · doi:10.1097/01213011-200504000-00002 · Cited by 267
Zhang, Z.-J., Yao, Z.-J., Liu, W., Fang, Q., & Reynolds, G. P. (2004) · British Journal of Psychiatry · doi:10.1192/bjp.184.1.58 · Cited by 230
Gender Differences in the Prescribing of Antipsychotic Drugs
Seeman, M. V. (2004) · American Journal of Psychiatry · doi:10.1176/appi.ajp.161.8.1324 · Cited by 219
Zipursky, R. B., Gu, H., Green, A. I., Perkins, D. O., Tohen, M. F., McEvoy, J. P., Strakowski, S. M., Sharma, T., Kahn, R. S., Gur, R. E., et al. (2005) · British Journal of Psychiatry · doi:10.1192/bjp.187.6.537 · Cited by 207
Adiponectin: A Key Player in Obesity Related Disorders
Matsuzawa, Y. (2010) · Current Pharmaceutical Design · doi:10.2174/138161210791208893 · Cited by 203
Capasso, R. M., Lineberry, T. W., Bostwick, J. M., Decker, P. A., & St. Sauver, J. (2008) · Schizophrenia Research · doi:10.1016/j.schres.2007.10.005 · Cited by 199
Ryan, M. C. M., Flanagan, S., Kinsella, U., Keeling, F., & Thakore, J. H. (2004) · Life Sciences · doi:10.1016/j.lfs.2003.08.044 · Cited by 186
Wu, R., Zhao, J., Liu, Z., Zhai, J., Guo, X., Guo, W., & Tang, J. (2006) · Psychopharmacology · doi:10.1007/s00213-006-0384-5 · Cited by 170
Crespo-Facorro, B., Pérez-Iglesias, R., Ramirez-Bonilla, M., Martínez-García, O., LLorca, J., & Vázquez-Barquero, J. L. (2006) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v67n1004 · Cited by 159
Baldwin, P. (2005) · Schizophrenia Bulletin · doi:10.1093/schbul/sbi025 · Cited by 153
Graham, K. A., Perkins, D. O., Edwards, L. J., Barrier, R. C., Lieberman, J. A., & Harp, J. B. (2004) · American Journal of Psychiatry · doi:10.1176/appi.ajp.162.1.118 · Cited by 151
Hennekens, C. H. (2007) · PubMed · Cited by 150
Strassnig, M., Miewald, J. M., Keshavan, M. S., & Ganguli, R. (2007) · Schizophrenia Research · doi:10.1016/j.schres.2007.02.024 · Cited by 135
Metabolic Risk Factors in Drug-Naive Patients With First-Episode Psychosis
Verma, S. K., Subramaniam, M., Liew, A., & Poon, L. Y. (2009) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.08m04508 · Cited by 132
Saddichha, S., Manjunatha, N., Ameen, S., & Akhtar, S. (2008) · Schizophrenia Research · doi:10.1016/j.schres.2008.01.004 · Cited by 131
Are the cardiometabolic complications of schizophrenia still neglected? Barriers to care
Lambert, T. J. R., & Newcomer, J. W. (2009) · The Medical Journal of Australia · doi:10.5694/j.1326-5377.2009.tb02374.x · Cited by 131
Pérez‐Iglesias, R., Crespo‐Facorro, B., Martínez‐García, O., Ramírez-Bonilla, M. L., Álvarez‐Jiménez, M., Pelayo‐Terán, J. M., García‐Unzueta, M. T., Amado, J., & Vázquez‐Barquero, J. L. (2007) · Schizophrenia Research · doi:10.1016/j.schres.2007.10.022 · Cited by 121
Weight gain in antipsychotic-naive patients: a review and meta-analysis
Tarricone, I., Gozzi, B. F., Serretti, A., Grieco, D., & Berardi, D. (2009) · Psychological Medicine · doi:10.1017/s0033291709990407 · Cited by 114
Binder, M. D., Correll, C. U., & Cohen, D. (2010) · Schizophrenia Research · doi:10.1016/j.schres.2009.12.029 · Cited by 112
Poyurovsky, M., Pashinian, A., Gil‐Ad, I., Maayan, R., Schneidman, M., Fuchs, C., & Weizman, A. (2002) · American Journal of Psychiatry · doi:10.1176/appi.ajp.159.6.1058 · Cited by 103
Glucose and lipid disturbances after 1 year of antipsychotic treatment in a drug-naïve population
Pérez‐Iglesias, R., Mata, I. F., Pelayo‐Terán, J. M., Amado, J., García‐Unzueta, M. T., Berja, A., Martínez‐García, O., Vázquez‐Barquero, J. L., & Crespo‐Facorro, B. (2008) · Schizophrenia Research · doi:10.1016/j.schres.2008.09.028 · Cited by 102
Pérez‐Iglesias, R., & Crespo‐Facorro, B. (2007) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v68n1113 · Cited by 102
Depression and Depressive Symptoms in First Episode Psychosis
Romm, K. L., Røssberg, J. I., Berg, A. O., Barrett, E. A., Færden, A., Agartz, I., Andreassen, O. A., & Melle, I. S. (2010) · The Journal of Nervous and Mental Disease · doi:10.1097/nmd.0b013e3181c81fc0 · Cited by 89
First-Episode Psychosis: Diagnostic Stability over One and Two Years
Haahr, U., Friis, S., Larsen, T. K., Melle, I. S., Johannessen, J. O., Opjordsmoen, S., Simonsen, E. H., Rund, B. R., Vaglum, P., & McGlashan, T. H. (2008) · Psychopathology · doi:10.1159/000146070 · Cited by 88
Saddichha, S., Manjunatha, N., Ameen, S., & Akhtar, S. (2008) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.2008.01158.x · Cited by 86
Pérez‐Iglesias, R., Vázquez‐Barquero, J. L., Amado, J., Berja, A., García‐Unzueta, M. T., Pelayo‐Terán, J. M., Carrasco-Marín, E., Mata, I. F., & Crespo‐Facorro, B. (2008) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e318172b8e6 · Cited by 83
Poyurovsky, M., Fuchs, C., Pashinian, A., Levi, A., Faragian, S., Maayan, R., & Gil‐Ad, I. (2007) · Psychopharmacology · doi:10.1007/s00213-007-0731-1 · Cited by 82
Cerebrovascular and Cardiovascular Complications of Alcohol and Sympathomimetic Drug Abuse
O’Connor, A. D., Rusyniak, D. E., & Bruno, A. (2005) · Medical Clinics of North America · doi:10.1016/j.mcna.2005.06.010 · Cited by 74
Spivak, B., Shabash, E., Sheitman, B., Weizman, A., & Mester, R. (2003) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v64n0703 · Cited by 73
Medical comorbidity in patients with schizophrenia and alcohol dependence
Batki, S. L., Meszaros, Z. S., Strutynski, K., Dimmock, J. A., Leontieva, L., Ploutz-Snyder, R., Canfield, K., & Drayer, R. A. (2009) · Schizophrenia Research · doi:10.1016/j.schres.2008.10.016 · Cited by 72
Predictors of Antipsychotic-Induced Weight Gain in First-Episode Psychosis
Saddichha, S., Ameen, S., & Akhtar, S. (2008) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e3181602fe6 · Cited by 69
Graham, K. A., Cho, H., Brownley, K. A., & Harp, J. B. (2008) · Schizophrenia Research · doi:10.1016/j.schres.2007.12.476 · Cited by 65
Crespo‐Facorro, B., Carrasco-Marín, E., Pérez‐Iglesias, R., Pelayo‐Terán, J. M., Fernández-Prieto, L., Leyva‐Cobián, F., & Vázquez‐Barquero, J. L. (2008) · Psychiatry Research · doi:10.1016/j.psychres.2006.08.005 · Cited by 63
Clinical trials for antipsychotic drugs: design conventions, dilemmas and innovations
Stroup, T. S., Alves, W. M., Hamer, R. M., & Lieberman, J. A. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd1956 · Cited by 62
Implementation of monitoring and management guidelines for second-generation antipsychotics.
Sernyak, M. J. (2007) · PubMed · Cited by 54
Pharmacokinetics and Therapeutic Drug Monitoring of Psychotropic Drugs in Pediatrics
Pichini, S., Papaseit, E., Joya, X., Vall, O., Farré, M., García‐Algar, Ó., & de la Torre, R. (2009) · Therapeutic Drug Monitoring · doi:10.1097/ftd.0b013e31819f3328 · Cited by 54
Verma, S. K., Liew, A., Subramaniam, M., & Poon, L. Y. (2009) · Australian & New Zealand Journal of Psychiatry · doi:10.1080/00048670903107609 · Cited by 51
DELEON, J., & Díaz, F. J. (2007) · Schizophrenia Research · doi:10.1016/j.schres.2007.05.020 · Cited by 42
Weight Gain in First-Episode Psychosis
Addington, J., Mansley, C., & Addington, D. E. (2003) · The Canadian Journal of Psychiatry · doi:10.1177/070674370304800412 · Cited by 42
Arranz, B., San, L., Dueñas, R., Centeno, M., Ramírez, N. D., Salavert, J., & del Moral, E. (2006) · Human Psychopharmacology Clinical and Experimental · doi:10.1002/hup.819 · Cited by 37
Attux, C. R. D. F., Quintana, M. I., & Chaves, A. C. (2007) · Brazilian Journal of Psychiatry · doi:10.1590/s1516-44462006005000061 · Cited by 35
Risperidone in the treatment of first episode psychosis.
Yap, H. L., Mahendran, R., Lim, D., Liow, P.-H., Lee, A., Phang, S., & Tiong, A. C. D. (2001) · PubMed · Cited by 35
Sengupta, S. M., Klink, R., Stip, É., Baptista, T., MALLA, A. K., & Joober, R. (2005) · Schizophrenia Research · doi:10.1016/j.schres.2005.07.024 · Cited by 34
The role of psychopharmacology in suicide prevention
Saunders, K. E. A., & Hawton, K. (2009) · Epidemiologia e Psichiatria Sociale · doi:10.1017/s1121189x00000427 · Cited by 34
Luty, J. S., Kelly, C., & McCreadie, R. G. (2002) · Journal of Substance Use · doi:10.1080/14659890110110374 · Cited by 11
Tarricone, I., Serretti, A., Gozzi, B. F., Mandelli, L., Grieco, D., Mellini, L., Biagini, S., Berti, B., & Berardi, D. (2007) · Psychiatry Research · doi:10.1016/j.psychres.2007.07.008 · Cited by 10
Cited by
Metabolic and cardiovascular adverse effects associated with antipsychotic drugs.
De Hert, M., Detraux, J., van Winkel, R., Yu, W., & Correll, C. U. (2012) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2011.156 · Cited by 1,145
Liu, N. H., Daumit, G. L., Dua, T., Aquila, R., Charlson, F., Cuijpers, P., Druss, B., Dudek, K., Freeman, M., Fujii, C., et al. (2017) · World Psychiatry · doi:10.1002/wps.20384 · Cited by 865
A systematic review and meta-analysis of exercise interventions in schizophrenia patients
Firth, J., Cotter, J., Elliott, R., French, P., & Yung, A. R. (2015) · Psychological Medicine · doi:10.1017/s0033291714003110 · Cited by 600
Barnes, T. R., Drake, R., Paton, C., Cooper, S. J., Deakin, B., Ferrier, I. N., Gregory, C. J., Haddad, P. M., Howes, O. D., Jones, I., et al. (2020) · Journal of Psychopharmacology · doi:10.1177/0269881119889296 · Cited by 606
Alvares, G. A., Quintana, D. S., Hickie, I. B., & Guastella, A. J. (2016) · Journal of Psychiatry and Neuroscience · doi:10.1503/jpn.140217 · Cited by 503
Metadata
- Authors
- Foley, D. L., & Morley, K. I.
- Venue
- Archives of General Psychiatry
- Publisher
- American Medical Association (AMA)
- Published
- 2011-06-06
- Volume
- 68
- Issue
- 6
- Pages
- 609
- ISSN
- 0003-990X (ISSN-L)
- OpenAlex
- W2141071939
- Cited by
- 287
- References
- 68
- FWCI
- 3.99
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.